Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.

Cell communication and signaling : CCS - 5 Jan 2026

Cipolletti Manuela, Bellucci Claudia, Fiocchetti Marco, Pavlin Matic, Magistrato Alessandra, Acconcia Filippo

Abstract excerpt

BACKGROUND: Metastatic breast cancer (MBC) remains a major clinical challenge, particularly in estrogen receptor α (ERα)-positive patients who develop resistance to endocrine therapy (ET). While hotspot mutations such as Y537S in the ligand-binding domain (LBD) are well-characterized drivers of resistance, other ERα variants remain poorly studied. Understanding the molecular mechanisms underlying resistance in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular Senescence
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Endocrine System

Share to Estrogen Receptor alpha

Share to Ligands

Share to Molecular Docking Simulation

Share to Neoplasm Metastasis

Share to Tretinoin

Source

Open in PubMed Open full text

Identifiers

PMID: 41491538
DOI: 10.1186/s12964-025-02639-5
PMCID: PMC12870731

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The natural L370F ERα variant confers endocrine resistance and sensitivity to ATRA in metastatic breast cancer cells.PMID 41491538Read ↗

The natural L370F ERα Variant Confers Endocrine Resistance and Sensitivity to ATRA in Metastatic Breast Cancer CellsSemantic proximity Read ↗

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses.Semantic proximity Read ↗

Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance.Semantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.Semantic proximity Read ↗

Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.Semantic proximity Read ↗

Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ERα−positive breast cancerSemantic proximity Read ↗

Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Semantic proximity Read ↗

Current Therapeutic Opportunities for Estrogen Receptor Mutant Breast CancerSemantic proximity Read ↗

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.Semantic proximity Read ↗

L370F and Y537S ESR1 mutations determine distinct endocrine therapy sensitivities and metabolic vulnerabilities that define new opportunities for synergistic therapeutic combinationsSemantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.